About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 459264, 7 pages
http://dx.doi.org/10.1155/2013/459264
Review Article

Integrative Western and Chinese Medicine on Coronary Heart Disease: Where Is the Orientation?

Siming Li1,2 and Hao Xu2

1Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
2Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Received 22 April 2013; Accepted 20 July 2013

Academic Editor: Keji Chen

Copyright © 2013 Siming Li and Hao Xu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Chen, “Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy,” Chinese Journal of Integrative Medicine, vol. 18, no. 12, pp. 891–896, 2012.
  2. H. Xu, D.-Z. Shi, and H.-J. Yin, “Blood-stasis and toxin causing catastrophe hypothesis and acute cardiovascular events: proposal of the hypothesis and its clinical significance,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 10, pp. 934–938, 2008. View at Scopus
  3. D.-Z. Shi, H. Xu, H.-J. Yin, J.-C. Zhang, and K.-J. Chen, “Combination and transformation of toxin and blood stasis in etiopathogenesis of thrombotic cerebrocardiovascular diseases,” Journal of Chinese Integrative Medicine, vol. 6, no. 11, pp. 1105–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Wen, H. Xu, and Q.-F. Huang, “Effect of drugs for promoting blood circulation on blood lipids and inflammatory reaction of atherosclerotic plaques in ApoE gene deficiency mice,” Journal of Chinese Integrative Medicine, vol. 25, no. 4, pp. 345–349, 2005. View at Scopus
  5. M.-X. Zhou, H. Xu, K.-J. Chen, and E. A. et al, “Effects of some active ingredients of Chinese drugs for activating blood circulation and detoxicating on blood lipids and atherosclerotic plaque inflammatory reaction in ApoE-gene knockout mice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 2, pp. 126–130, 2008. View at Scopus
  6. H. Xu, D. Qu, and F. Zheng, “Clinical manifestations of “blood-stasis and toxin” in patients with stable coronary heart disease,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 30, no. 22, pp. 125–129, 2010.
  7. Y. Feng, H. Xu, D. Qu, F. Zheng, D.-Z. Shi, and K.-J. Chen, “Study on the tongue manifestations for the blood-stasis and toxin syndrome in the stable patients of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 5, pp. 333–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Xue, H. J. Yin, and C. F. Wu, “Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome,” Chinese Journal of Integrative Medicine, vol. 19, no. 1, pp. 42–47, 2013.
  9. K. J. Chen, D. Z. Shi, and H. Xu, “The criterion of syndrome differentiation and quantification for stable coronary heart disease caused by etiological toxin of Chinese medicine,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 31, no. 3, pp. 313–314, 2011.
  10. X. Wang and D. Y. Hu, “Clinical study on the hypothesis of ‘endogenous collateral wind’on acute coronary syndrome,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 23, no. 3, pp. 204–208, 2008.
  11. J. B. Zhong, S. Y. Dong, J. Wang, et al., “Literature analysis on syndrome elements of 2689 patients with angina pectoris,” Chinese Journal of Information on TCM, vol. 13, no. 5, pp. 100–101, 2006.
  12. J. X. Zhou, M. Tang, and J. Li, “Analysis of Chinese syndrome features and combination laws of 2029 patients with coronary heart disease angina,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 31, no. 6, pp. 753–755, 2011.
  13. H.-L. Wu, X.-M. Ruan, and X.-B. Yang, “Analysis on TCM syndrome distribution laws in 319 patients with coronary heart disease,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 27, no. 6, pp. 498–500, 2007. View at Scopus
  14. X. C. Wang, Y. B. Nong, Q. Lin, et al., “Analysis on the combination characteristics of TCM syndromes of 138 cases with coronary heart disease,” Journal of Traditional Chinese Medicine, vol. 49, no. 1, pp. 62–63, 2008.
  15. L. Wang, H. X. Liu, Z. D. Zou, et al., “Research on TCM syndrome characteristics of hospitalized patients with acute myocardial infarction in TCM hospitals of Beijing,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 6, no. 4, pp. 379–380, 2008.
  16. J. Wang, Y. W. Xing, K. W. Yao, et al., “Study on Chinese medicine syndrome elements of coronary heart disease angina pectoris and its clinical applications,” Journal of Hubei College of Traditional Chinese Medicine, vol. 11, no. 3, pp. 3–5, 2009.
  17. Y. Ren, Y. Wu, M. Z. Zhang, et al., “Study on Chinese medicine syndromes characteristics and distribution rule around percutaneous coronary intervention perioperative period,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 8, no. 6, pp. 639–641, 2010.
  18. G. R. Yu, Y. Q. He, Y. G. Guo, et al., “Clinical studies on relationship of traditional Chinese medicine syndrome of Coronary heart disease with insulin resistance, lipids and erythrocyte membrane atpase,” Journal of Traditional Chinese Medicine, vol. 41, no. 2, pp. 111–112, 2002.
  19. D. X. Wei, M. Liu, Y. C. Pang, et al., “Study on the correlation between Chinese medicine syndrome types and blood lipid levels in patients with coronary heart disease,” Journal of Emergency in Traditional Chinese Medicine, vol. 19, no. 3, pp. 441–442, 2010.
  20. G. Shi and T. Liu, “Clinical epidemiological investigation on Chinese medicine syndrome in patients with Coronary heart disease,” Chinese Archives of Traditional Chinese Medicine, vol. 25, no. 8, pp. 1675–1676, 2007.
  21. C.-J. Bai, Y. Zhou, L. Wang, D.-L. Zhang, and Y. Yang, “Delamination of cardiovascular risk factor, staging and grading of hypertension and the changing characteristics of blood lipids and hemorheological indexes in hypertensive patients with different syndromes of traditional Chinese medicine,” Chinese Journal of Clinical Rehabilitation, vol. 9, no. 23, pp. 145–147, 2005. View at Scopus
  22. Y. W. Xing, J. Wang, Y. H. Gao, et al., “Study on characters of TCM syndrome and pathological changes of coronary artery in patients of coronary artery disease combined with diabetes,” Chinese Journal of Information on TCM, vol. 14, no. 9, pp. 20–21, 2007.
  23. Y. Ren, M. Z. Zhang, K. J. Chen et al., “Clinical and epidemiological investigation of TCM syndromes of patients with coronary heart disease in China,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714517, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. C. G. Fu, Z. Y. Gao, and P. L. Wang, “Study on the diagnostic criteria for coronary heart disease patients of blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 9, pp. 1285–1286, 2012.
  25. L. J. Mei, S. Q. Xiong, T. Wang, et al., “A case control study of influential factors for the Han population with coronary heart disease of blood stasis syndrome in Fuzhou area,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 2, pp. 168–171, 2012.
  26. O. Li and H. Xu, “The occurrence of cardiovascular events of coronary heart disease inpatients and study on Chinese medicine syndrome distribution laws,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 5, pp. 603–606, 2012.
  27. S. W. Li, Study on evolution rule of Chinese medicine syndrome in stable phase of coronary heart disease [Ph.D. thesis], Beijing University of Traditional Chinese Medicine, Beijing, China, 2011.
  28. X. T. Yu, L. Zhang, and H. Xu, “Progress in research on relevant factors affectingTCM syndrome differentiation of CHD,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 7, no. 5, pp. 581–584, 2009.
  29. X.-J. Ma, H.-J. Yin, and K.-J. Chen, “Investigation of gene expression profiles in patients with blood stasis syndrome,” Journal of Chinese Integrative Medicine, vol. 6, no. 4, pp. 355–360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. K. Yuan, L. P. Wang, and X. P. Huang, “The screening and the functional pathway analysis of differential genes correlated with coronary heart disease of blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 10, pp. 1314–1318, 2012.
  31. H. J. Wu, Z. C. Ma, Y. Gao, et al., “Study on GAP in blood-stasis type of coronary heart disease by using proteomic technique,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 3, no. 3, pp. 189–191, 2005.
  32. X. F. Li, Y. R. Jiang, Z. Y. Gao, et al., “Screening, identification and analysis of platelet differential functional proteins in patients with coronary heart disease of blood-stasis pattern,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 30, no. 5, pp. 467–473, 2010.
  33. H.-H. Zhao, N. Hou, and W. Wang, “Study on proteomic specificity of unstable angina with qi deficiency and blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 6, pp. 489–492, 2009. View at Scopus
  34. X. Y. Lu, H. Xu, G. Li, and T. Zhao, “Study on correspondence between prescription and syndrome and the essence of phlegm and blood stasissyndrome in coronary heart disease based on metabonomics,” Chinese Journal of Integrative Medicine, 2012. View at Publisher · View at Google Scholar
  35. W. X. Jian, Z. K. Yuan, and X. P. Huang, “Detection and analysis on plasma metabolomics in patient with coronary heart disease of xin-blood stasis syndrome pattern,” Chinese Journal of Integrative Medicine, vol. 30, no. 6, pp. 579–584, 2010.
  36. Z. Lu, W. Kou, B. Du et al., “Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction,” American Journal of Cardiology, vol. 101, no. 12, pp. 1689–1693, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. K.-J. Chen, D.-Z. Shi, H. Xu et al., “XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China,” Chinese Medical Journal, vol. 119, no. 1, pp. 6–13, 2006. View at Scopus
  38. Q.-H. Shang, H. Xu, X.-Y. Lu, C. Wen, D.-Z. Shi, and K.-J. Chen, “A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients,” Chinese Journal of Integrative Medicine, vol. 17, no. 9, pp. 669–674, 2011. View at Scopus
  39. F. Tian and Y.-M. Xie, “Real-world study: a potential new approach to effectiveness evaluation of traditional Chinese medicine interventions,” Journal of Chinese Integrative Medicine, vol. 8, no. 4, pp. 301–306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Z.-Y. Gao, H. Xu, D.-Z. Shi, C. Wen, and B.-Y. Liu, “Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine,” Journal of Ethnopharmacology, vol. 141, no. 2, pp. 578–583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Luo and H. Xu, “Outcome measures of Chinese herbal medicine for coronary heart disease: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 927392, 9 pages, 2012. View at Publisher · View at Google Scholar
  42. K. F. Schulz, D. G. Altman, D. Moher, and CONSORT Group, “CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials,” Annals of Internal Medicine, vol. 152, no. 11, pp. 726–732, 2010. View at Scopus
  43. Y. Qiu, H. Xu, and D. Shi, “Traditional chinese herbal products for coronary heart disease: an overview of cochrane reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 417387, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Xu and K.-J. Chen, “Herb-drug interaction: an emerging issue of integrative medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 3, pp. 195–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. N. J. Wald and M. R. Law, “A strategy to reduce cardiovascular disease by more than 80%,” British Medical Journal, vol. 326, no. 7404, pp. 1419–1423, 2003. View at Scopus
  46. Y. Feng, H. Xu, and K. J. Chen, “Natural polypill xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions,” Journal of Alternative Complementary Medicine, vol. 18, no. 4, pp. 318–328, 2012.
  47. A. Tachjian, V. Maria, and A. Jahangir, “Use of herbal products and potential interactions in patients with cardiovascular diseases,” Journal of the American College of Cardiology, vol. 55, no. 6, pp. 515–525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Xu and K.-J. Chen, “Making evidence-based decisions in the clinical practice of integrative medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 6, pp. 483–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. X.-F. Yan, Q. Ni, J.-P. Wei, and H. Xu, “Evidence-based practice method of integrative Chinese and western medicine based on literature retrieval through PICO question and complementary and alternative medicine topics,” Chinese Journal of Integrative Medicine, vol. 16, no. 6, pp. 542–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Y. Tan, T. Jiang, C. P. Tang, J.-L. Luo, H.-T. Tan, and R.-S. Chen, “The inhibitory effect of tetramethylpyrazine and ferulate on platelet aggregation,” Chinese Journal of New Drugs, vol. 12, no. 7, pp. 529–531, 2003.
  51. F. Norol, P. Merlet, R. Isnard et al., “Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model,” Blood, vol. 102, no. 13, pp. 4361–4368, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. N.-Y. Wang, C.-J. Lu, and X.-H. Chen, “Study on effect of ginsenoside Rg1 in promoting myocardiac vascular endothelial cell regeneration through induction on bone marrow stem cell's migration and differentiation in rabbits of myocardial infarction,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 25, no. 10, pp. 916–919, 2005. View at Scopus
  53. L. D. Li, R. L. Zhang, C. Y. Liu, et al., “The effects of Shuanglongfang therapy plus bone marrow mononuclear cells autotransplantation on myocardial infarction in swines,” Chinese Journal of New Drugs, vol. 12, no. 12, pp. 999–1004, 2003.